Julie R. Park, MD

Julie R. Park, MD

Cancer and Blood Disorders Center, Neuroblastoma Program, Bone Tumors and Soft Tissue Tumors, Apheresis, I-131-MIBG Therapy, Solid Tumors Oncology

Academic Title: Professor of Pediatrics, UW School of Medicine; Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center

Foundation Title: Bushnell, Towne & Wilkerson Endowed Chair in Pediatric Neuroblastoma and Medical Director Immunotherapy Coordinating Center

Research Center: Center for Clinical and Translational Research

"My goal is to improve cure rates for childhood cancer through the development of novel therapies that lead to long-term cure of cancer without devastating side effects."

  • Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is the scientific lead for the New Approaches to Neuroblastoma Therapy (NANT) consortium, funded through a NCI Program Project Grant: “Discovering and exploiting mechanisms of neuroblastoma therapy resistance.” 

    My research is focused on translating laboratory discoveries to improve the survival of children with cancer. I have a strong track record of collaborating with investigators to identify clinical applications of laboratory discoveries and have translated laboratory findings into development of early phase clinical trials for recurrent childhood malignancies.

    Through collaboration with Dr. Michael Jensen, I have been instrumental in the development of Seattle Children’s Therapeutics, an organization within Seattle Children’s devoted to the development of novel cellular immunotherapy trials for pediatric disease. We have developed first-in-human autologous chimeric antigen receptor (CAR) T cell trials for wide spectrum of pediatric cancers including solid tumors, brain tumors, leukemia and lymphoma.

    I also have a major area of focus in the development of novel therapy for neuroblastoma. In this regard, I am the past chair of the Children’s Oncology Group Neuroblastoma Scientific Committee and led research that incorporated our understanding of neuroblastoma biology into improved prognostic stratification and novel targeted therapeutics. I am currently the scientific lead for the New Approaches to Neuroblastoma Therapy (NANT) consortium, funded through a NCI Program Project Grant: “Discovering and exploiting mechanisms of neuroblastoma therapy resistance” that is focused on translating laboratory discoveries to novel therapies for children with neuroblastoma. 

    • Related Pages

    • Gaining Ground on Neuroblastoma

      We helped show that two stem cell transplants, plus immunotherapy, significantly increased survival for children with high-risk neuroblastoma.

    • Tracey Seattle, WA 06.22.14

      Dr. Park is my daughter's Doctor. Just saying those words bring hope. I know Dr. Park is absolutely invested in saving children's lives and that she works tirelessly at finding new ways to do so. We may have traveled off the beaten path, where treatment for my daughter is concerned, but only to find that Dr. Park has laid pavement. Not sure what the outcome for my child will be, but I know that Dr. Park is doing all she can to save her. Thank you Dr. Park.

    • Heather Redmond, WA 07.10.13

      Dr. Park did a wonderful job in her medical treatment of my daughter! We began the journey full of fears and worries, and we are so fortunate to have had the best possible outcome. I firmly believe that much of this is due to Dr. Park's wealth of experience, close monitoring and her willingness to listen to my concerns. I always feel that my daughter's best interests are Dr. Park's primary concern, and she has always been very compassionate and caring towards me - even when I was having a hard time coming to grips with what was happening. Anyone who has Dr. Park as their child's oncologist is very lucky to have her!

    Recommend Julie R. Park, MD
  • Award Name Award Description Awarded By Award Date
    SEATTLE'S TOP DOCTOR - 2019 Seattle Magazine 2019
    SEATTLE'S TOP DOCTOR - 2018 Seattle Magazine 2018
    Frank Oski Award American Society of Pediatric Hematology and Oncology 2018
    SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017
    Seattles Top Doctor 2016 Seattle Met Magazine 2016
    SEATTLE MAGAZINE TOP DOCTOR - 2016 Seattle Magazine 2016
    SEATTLE MAGAZINE TOP DOCTOR - 2015 Seattle Magazine 2015
    SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
    Seattle's Top Doc Seattle Met Magazine 2013
    Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
    Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
    U.S. News Top Doctor U.S. News and World Report 2012
    Bushnell Towne Wilkerson Endowed Chair in Pediatric Neuroblastoma 2009
    Benjamin Towne Endowed Chair in Neuroblastoma Benjamin Towne Foundation 2009
    William Guy Forbeck Research Foundation Scholar Award William Guy Forbeck Research Foundation 1995
    Newsweek Health: Top Cancer Doctors 2015 Newsweek 2015

  • Other Publications

    • Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM
      Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
      33504555 Clinical cancer research : an official journal of the American Association for Cancer Research, 2021 April 15 : 27(8)2179-2189 PMCID:PMC8046731
    • Granger MM, Naranjo A, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, London WB, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA
      Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
      33823167 Transplantation and cellular therapy, 2021 March 6
    • Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H
      Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
      33739795 The American journal of surgical pathology, 2020 Dec. 22
    • Ambros IM, Tonini GP, Pötschger U, Gross N, Mosseri V, Beiske K, Berbegall AP, Bénard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh EF, Hogarty MD, Monclair TF, Holmes K, Valteau-Couanet D, Castel V, Tweddle DA, Park JR, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson ADJ, Ambros PF
      Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
      32903140 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Nov. 1 : 38(31)3685-3697 PMCID:PMC7605396
    • Mack JW, Uno H, Twist CJ, Bagatell R, Rosenberg AR, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park JR, Cohn SL, Fernandez JH, Diller LR, Shusterman S
      Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer.
      32360991 Journal of pain and symptom management, 2020 Oct. : 60(4)782-789 PMCID:PMC7523916
    • Goldberg J, Sulis ML, Bender J, Jeha S, Gardner R, Pollard J, Aquino V, Laetsch T, Winick N, Fu C, Marcus L, Sun W, Verma A, Burke M, Ho P, Manley T, Mody R, Tcheng W, Thomson B, Park J, Sposto R, Messinger Y, Hijiya N, Gaynon P, Barredo J
      A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies.
      32338562 Pediatric hematology and oncology, 2020 Sept. : 37(6)465-474
    • Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, Buckland S, Caron H, Davis S, De Wilde B, Deubzer HE, Dolman E, Eilers M, George RE, George S, Jaroslav Å , Maris JM, Marshall L, Merchant M, Mortimer P, Owens C, Philpott A, Poon E, Shay JW, Tonelli R, Valteau-Couanet D, Vassal G, Park JR, Pearson ADJ
      Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
      32653773 European journal of cancer (Oxford, England : 1990), 2020 Sept. : 13652-68
    • Liu KX, Naranjo A, Zhang FF, DuBois SG, Braunstein SE, Voss SD, Khanna G, London WB, Doski JJ, Geiger JD, Kreissman SG, Grupp SA, Diller LR, Park JR, Haas-Kogan DA
      Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study.
      32530765 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Aug. 20 : 38(24)2741-2752 PMCID:PMC7430214
    • Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R
      Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
      32343642 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 July 1 : 38(19)2160-2169 PMCID:PMC7325366
    • Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB
      Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
      32315273 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 June 10 : 38(17)1906-1918 PMCID:PMC7280049
    • Mack JW, Cronin AM, Uno H, Shusterman S, Twist CJ, Bagatell R, Rosenberg A, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park J, Cohn SL, Levine A, Taddei S, Diller LR
      Unrealistic parental expectations for cure in poor-prognosis childhood cancer.
      31584705 Cancer, 2020 Jan. 15 : 126(2)416-424 PMCID:PMC7523918
    • Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, Finney OC, Brakke H, Li DH, Park JR, Jensen MC
      Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
      31697826 Blood, 2019 Dec. 12 : 134(24)2149-2158 PMCID:PMC6908832
    • Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL
      Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
      31386611 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019 Dec. 1 : 37(34)3243-3255 PMCID:PMC6881103
    • Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM
      Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
      31358541 Clinical cancer research : an official journal of the American Association for Cancer Research, 2019 Oct. 15 : 25(20)6044-6051 PMCID:PMC6945765
    • Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L
      Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
      31454045 JAMA, 2019 Aug. 27 : 322(8)746-755 PMCID:PMC6714031
    • Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, Gamble DN, Rawlings-Rhea SD, Khalatbari HK, Ishak GE, Duncan VE, Hevner RF, Jensen MC, Park JR, Gardner RA
      Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.
      31074527 Annals of neurology, 2019 July : 86(1)42-54
    • Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA
      Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.
      30968542 Pediatric blood & cancer, 2019 July : 66(7)e27736 PMCID:PMC7281832
    • Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB
      Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System.
      30652588 JCO clinical cancer informatics, 2018 Dec. : 21-15 PMCID:PMC6421832
    • Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM
      Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621).
      24347462 Pediatric blood & cancer, 2013 Dec. 18
    • Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H
      Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
      23901000 Cancer, 2013 Oct. 15 : 119(20)3718-26
    • Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG
      Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
      23890779 The lancet oncology, 2013 Sept. : 14(10)999-1008
    • Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA
      A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
      23334272 Bone marrow transplantation, 2013 July : 48(7)947-52 PMCID:PMC3638062
    • Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, Hogarty M, COG Neuroblastoma Committee
      Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
      23255319 Pediatric blood & cancer, 2013 June : 60(6)985-93
    • Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK
      Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
      23440556 Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013 April : 54(4)541-8
    • Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H
      Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
      22744966 Pediatric blood & cancer, 2013 March : 60(3)363-70 PMCID:PMC3397468
    • Moreno L, Barone G, Park JR, Pearson AD
      About the benefits of immunotherapy for high-risk neuroblastoma.
      23295791 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013 Feb. 10 : 31(5)649-50
    • Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJ
      Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
      22883417 American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012 Nov. : 12(11)3069-75 PMCID:PMC3484187
    • Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR
      A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
      22791883 Clinical cancer research : an official journal of the American Association for Cancer Research, 2012 Sept. 15 : 18(18)5081-9 PMCID:PMC3445751
    • Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori C
      Functional genomics identifies therapeutic targets for MYC-driven cancer.
      22623531 Proceedings of the National Academy of Sciences of the United States of America, 2012 June 12 : 109(24)9545-50 PMCID:PMC3386069
    • Fisher BT, Zaoutis TE, Park JR, Bleakley M, Englund JA, Kane C, Arceci RJ, Guinan E, Smith FO, Luan X, Marr KA
      Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients.
      23687575 Journal of the Pediatric Infectious Diseases Society, 2012 June : 1(2)103-111 PMCID:PMC3656552
    • Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA
      Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
      21976622 Drug metabolism and disposition: the biological fate of chemicals, 2012 Jan. : 40(1)54-63 PMCID:PMC3250049
    • Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK
      Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
      22010014 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011 Nov. 20 : 29(33)4351-7 PMCID:PMC3221519
    • Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM
      Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
      21340605 Cancer chemotherapy and pharmacology, 2011 Oct. : 68(4)1057-65
    • Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG
      A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
      21671363 Pediatric blood & cancer, 2011 Aug. : 57(2)275-82 PMCID:PMC3117015
    • Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC
      Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
      20606092 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010 Aug. 1 : 3623-9
    • Park JR, Eggert A, Caron H
      Neuroblastoma: biology, prognosis, and treatment.
      20113896 Hematology/oncology clinics of North America, 2010 Feb. : 65-86
    • Fong A, Park JR
      High-risk neuroblastoma: a therapy in evolution.
      19954363 Pediatric hematology and oncology, 2009 Nov. : 539-48
    • Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK
      Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
      19171709 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009 March 10 : 1290-6
    • Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK
      Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
      18937318 Pediatric blood & cancer, 2009 Jan. : 44-50
    • McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR
      Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.
      18927240 Journal of clinical pharmacology, 2009 Jan. : 88-102
    • Tasian SK, Park JR, Martin ET, Englund JA
      Influenza-associated morbidity in children with cancer.
      18240170 Pediatric blood & cancer, 2008 May : 983-7
    • Park JR, Eggert A, Caron H
      Neuroblastoma: biology, prognosis, and treatment.
      18242317 Pediatric clinics of North America, 2008 Feb. : 97-120, x
    • Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC
      Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
      17299405 Molecular therapy : the journal of the American Society of Gene Therapy, 2007 April : 825-33
    • Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC
      Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
      16170157 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005 Sept. 20 : 6481-8
    • Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS
      Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
      15382275 Pediatric blood & cancer, 2004 Oct. : 571-9
    • Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI
      Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
      15328169 Clinical cancer research : an official journal of the American Association for Cancer Research, 2004 Aug. 15 : 5335-41
    • Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR
      Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
      15022296 Cancer, 2004 March 15 : 1268-75
    • Wright JA, Bradfield SM, Park JR, Hawkins DS
      Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
      12679641 Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology, 2003 April : 286-91
    • Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T
      Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
      12461792 Medical and pediatric oncology, 2003 Feb. : 93-8

    Show More Hide

  • Presentations Title Event Location Date
    CAR T cell for Pediatric Solid Tumors Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Virtual Feb. 2021
    CAR T cell for Pediatric Solid Tumors Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Annual Meeting Virtual Feb. 2021
    Neuroblastoma: A Paradigm for Pediatric Cancer Therapy University of Washington School of Medicine Science in Medicine Lecture Seattle, WA March 2020
    Neuroblastoma: A Paradigm for Pediatric Cancer Therapy University of Washington School of Medicine Science in Medicine Lecture Seattle, WA March 2020
    Taking Next Generation CAR T cell Therapy Beyond Leukemia Children’s Hospital Los Angeles Pediatric Oncology Seminar Los Angeles, CA Feb. 2020
    New Directions In Treating High Risk Neuroblastoma SIOP Lyons, France Nov. 2019
    COG Neuroblastoma Update SIOPEN Annual Meeting Krakow, Poland Oct. 2019
    Expanding CAR T cell therapy to a wide spectrum of pediatric malignancies AACR: Immune Cell Therapies for Cancer San Francisco, CA July 2019
    High Risk Neuroblastoma Therapy: A Collaborative Story Stanford University Palo Alto, CA April 2019
    Taking Next Generation CAR T cell Therapy to a Broad Spectrum of Pediatric Cancer AACR Annual meeting Atlanta, GA April 2019
    Cellular Immunotherapy for Childhood Cancer Dana Farber Cancer Center Boston, MA Feb. 2019
    Neuroblastoma and Wilms Tumor American Society of Pediatric Oncology Review Course Dallas, TX Jan. 2019
    High Risk Neuroblastoma: Improving Induction Therapy SIOP Kyoto, Japan Nov. 2018
    High Risk Neuroblastoma: Therapy at Diagnosis and Relapse, COG Update SIOPEN Annual Meeting Jeruselam, Israel Oct. 2018
    Strategies for improving neuroblastoma outcome using anti-GD2 immunotherapy Advances in Neuroblastoma Research San Francisco, CA May 2018
    Improvements in Neuroblastoma Therapy: The Fruits of Collaboration ASPHO Oski Lectureship Pittsburg, PA May 2018
    Treatment of High Risk Neuroblastoma. Oncology Grand Rounds, Toronto Sick Kids Toronto, Canada Jan. 2018
    High Risk Neuroblastoma: Complex Success Neuroblastoma and Brain Tumor Symposium Uppsala, Sweden Nov. 2017
    COG Neuroblastoma Update SIOPEN annual meeting Berlin, Germany Oct. 2017
    Molecular or Immunotherapy Targeting in Neuroblastoma New Drug Development Strategy Meeting Cambridge, England Sept. 2017
    High Risk Neuroblastoma: Biology to Clinical care Baylor/Texas Children’s Symposium Houston, TX May 2017
    Neuroblastoma and Wilms Tumor American Society of Pediatric Oncology Review Course Dallas, TX Feb. 2017
    New Therapies for High Risk Neuroblastoma Advances in Neuroblastoma Research, Parent Conference Cairns, Australia June 2016
    Novel Clinical Trial Design Advances in Neuroblastoma Research Cairns, Australia June 2016
    Improving Outcomes in High Risk Neuroblastoma Advances in Neuroblastoma Research Cairns, Australia June 2016
    Improving Outcome In Neuroblastoma Through Cooperative Clinical Trials American Society of Clinical Oncology Education Session Chicago, IL June 2016
    International Neuroblastoma Risk Group Staging System (INRGSS): Influence on Treatment American Society of Pediatric Hematology Oncology Annual Meeting Phoenix, AZ April 2015
    Neuroblastoma and Wilms Tumor American Society of Pediatric Oncology Review Course Dallas, TX Feb. 2015
    High Risk Neuroblastoma: Therapy - New Directions Japanese Society of Pediatric Hematology and Oncology Okyama, Japan Nov. 2014
    COG Neuroblastoma Update Japanese Society of Pediatric Hematology and Oncology Okyama, Japan Nov. 2014
    High Risk Neuroblastoma Therapy Approaches SIOPEN Annual Meeting Vienna, Austria Oct. 2014
    Neuroblastoma: Therapy Beyond the Malignant Cell? Forbeck Annual Meeting Atlanta, GA Sept. 2014
    High Risk Neuroblastoma: COG update Advances in Neuroblastoma Research Cologne, Germany June 2014
    High Risk Neuroblastoma Therapy: Improving the Outcome New Approaches to Neuroblastoma Therapy Consortium Annual Meeting, Plenary Lecture Los Angeles, CA March 2014
    Treatment Strategies for High Risk Neuroblastoma SIOPEN Annual Meeting Paris, France Oct. 2013
    Neuroblastoma and Wilms Tumor American Society of Pediatric Oncology Review Course Dallas, TX Feb. 2013
    Neuroblastoma Biology and Treatment: Next Steps International Neuroblastoma Pathology Symposium Los Angeles, CA Feb. 2013
    Meet the Professor: Therapeutic Strategies for Neuroblastoma International Society of Pediatric Oncology (SIOP) London, England Oct. 2012
    Neuroblastoma – Progress in the Treatment of High Risk Disease COG Education Session Atlanta, GA Sept. 2012
    Neuroblastoma – Perspective of Children’s Oncology Group SIOPEN meeting Ghent, Belgium Sept. 2012
    HSCT improves outcome for high risk neuroblastoma. What’s Next? Advances in Neuroblastoma Research, Plenary Session Discussant Toronto, Canada June 2012
    Translating Biology to the Treatment of Neuroblastoma International Society of Pediatric Oncology-Neuroblastoma; Translational Medicine Symposium London, England Oct. 2011
    Results from the HR NBL1/SIOPEN Trial Plenary Session Discussant, American Society of Clinical Oncology Chicago, IL June 2011
    Novel Prognostic and Therapeutic Advances for High Risk Neuroblastoma: Continued Progress Towards a Cure Translational Approaches to Neuroblastoma Symposium Cinncinatti, OH May 2011
    Update: Children’s Oncology Group Neuroblastoma Clinical Trials International Society of Pediatric Oncology-Neuroblastoma; General Meeting Porto, Portugal Oct. 2010
    Accessing Novel Therapies and Navigating the Maze: The Pediatric Oncologist's Perspective American Society of Clinical Oncology, Educational Session Orlando, FL June 2009
    Targeting Treatment to Improve Outcomes for Childhood Cancer Circle of Care Symposium, Seattle Children’s Hospital Seattle, WA May 1, 2009
    Infectious Complications of Pediatric Cancer Advanced Oncology Nursing unknown Feb. 1, 2009
    Stage 3 Neuroblastoma: Diagnostic Dilemma International Society of Pediatric Oncology-Neuroblastoma; General Meeting Lucerne, Switzerland Oct. 2008
    New directions for treatment of high risk neuroblastoma: A Children’s Oncology Group Perspective American Society of Clinical Oncology, Educational Session Chicago, IL June 2007
    Neuroblastoma: New Advances Stem Cell Transplantation in Children, Current Results and Controversies San Diego, CA Jan. 2007
    New chemotherapy approaches to neuroblastoma Rebecca Gunzman Memorial Pediatric Oncology Symposium City of Hope National Medical Center, Duarte, CA March 2002
    Neuroblastoma – Diagnosis and Treatment American Physician Assistants Organization, Seminars in Clinical Oncology Seattle, WA Aug. 1999
    Myeloablative therapy for Pediatric Solid Tumors Academy of Pediatric Oncology Nurses, National Meeting Seattle, WA Sept. 1998
  • Grant Title Grantor Amount Award Date
    Accelerating the development of lorlatinib to improve cure rates for patients newly diagnosed ALK-driven high-risk neuroblastoma Solving Kids' Cancer $51,769 Dec. 1, 2020 - Nov. 30, 2014
    Prospective evaluation of barriers to patient referral and enrollment in emerging cellular therapy trials: determining methods and structure to improve equity in future trial design NIH/NCI $159,801 Sept. 9, 2020 - July 31, 2021
    L1CAM Chimeric Antigen Receptor T Cell Therapy for Small Cell Neuroendocrine Prostate Cancer Prostate Cancer Foundation $62,869 Oct. 11, 2019 - Oct. 20, 2021
    Pediatric Cancer Data Commons St. Baldrick’s Foundation $78,532 July 1, 2019 - June 30, 2022
    Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders NIH/NCI $7,067,486 Aug. 1, 2018 - July 31, 2023
    New Approaches to Neuroblastoma Therapy – Extended Funding The V Foundation for Cancer Research $47,485 Oct. 1, 2017 - Nov. 1, 2021
    Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance. Core B: Clinical Trials and Translation NIH/NCI $124,973 Sept. 18, 2017 - Aug. 31, 2022
    The Plasma Membrane Monoamine Transporter (PMAT): Expression and Role in mIBG Disposition in Neuroblastoma NIH/NIGMS $66,683 Aug. 5, 2017 - May 31, 2021
    Accelerating Access to Cellular Therapies for the Treatment of Childhood Malignancies Alex’s Lemonade Stand Foundation $935,023 Jan. 1, 2014 - Dec. 21, 2023
    Immunogenomics to Create New Therapies for High-Risk Childhood Cancers Stand Up To Cancer & St. Baldrick’s Foundation Pediatric Dream Team Translational Cancer Research $422,381 July 1, 2013 - Nov. 30, 2021
    Cancer Immunotherapy Trials Network Central Operations and Statistical Center – PedCITN Vice Chair NIH/NCI $201,490 Sept. 21, 2010 - Aug. 31, 2022

Overview

Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

University of Vermont College of Medicine, Burlington

Clinical Interests

Neuroblastoma, Solid tumors

Research Description

My research is focused on translating laboratory discoveries to improve the survival of children with cancer. I have a strong track record of collaborating with investigators to identify clinical applications of laboratory discoveries and have translated laboratory findings into development of early phase clinical trials for recurrent childhood malignancies.

Research Focus Area

Refractory and recurrent cancer, Sarcomas, Thyroid Cancer, Cancer biology, Neuroblastoma, Cancer